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ercutaneous Revascularization for
table Coronary Artery Disease
emporal Trends and
mpact of Drug-Eluting Stents
e read with great interest the paper by Hilliard et al. (1) in JACC:
ardiovascular Interventions and congratulate the investigators on a
ery well-done and important analysis. Many of those who have
riticized the COURAGE (Clinical Outcomes Utilizing Revascu-
arization and Aggressive Drug Evaluation) study as not being
generalizable” to contemporary clinical practice (e.g., only 6% of
creened patients were randomized, percutaneous coronary inter-
ention [PCI] was substandard, too many patients enrolled from
eterans Affairs and Canada, very low rate of drug-eluting stent
sage, adherence to optimal medical therapy was not achievable in
he real world) should be reassured by the Mayo Clinic data. The
ayo data indicate that procedural success and technical profi-
iency continue to evolve and improve, in-hospital mortality and
arget vessel revascularization continue to decline, and results
chievable in the real world might even be better if more robust
ptimal medical therapy were more widely embraced and used.
The fact that the rates of death, death/myocardial infarction
MI), and revascularization in COURAGE at 4.6 years are
irtually identical to the rates reported from Mayo at 4 years
upports the concept suggested by the results of COURAGE that
hese late events (and need for subsequent revascularization) are
ot being driven by the stenoses that are initially “being fixed,” but
ather by new plaque ruptures in non-flow-limiting vessels. More-
ver, we note that the patient population undergoing PCI at Mayo
etween 1997 and 2003 was remarkably similar to patients enrolled
n COURAGE during the same time period. Table 4 of Hilliard
t al. (1) cites certain baseline characteristics of the Mayo popu-
ation that were higher risk than those of the COURAGE
opulation, but the investigators do not comment on the higher
ates of diabetes (32% vs. 24%), multivessel coronary artery disease
69% vs. 51%), and left anterior descending coronary artery disease
68% vs. 47%) in the COURAGE PCI cohort as compared with
he Mayo patients (2,3). Additionally, in their Table 1 (1), only
3% of patients in the Mayo Clinic cohort had a positive stress test
s the predominant indication for PCI, whereas in COURAGE,
ll patients had objective evidence of myocardial ischemia (2,3).
hus, when a more comprehensive list of characteristics is ana-
yzed it appears the Mayo and COURAGE PCI cohorts were
ndeed very comparable populations of North American stable
ngina patients. This is underscored further by the performance
nd outcomes of the PCI procedures that were very comparable in
oth studies and similar to contemporary practice in the National gardiovascular Data Registry (4). The difference in procedural
uccess noted in Table 4 (89% vs. 94%) of Hilliard et al. (1) is likely
ue to differing definitions (COURAGE excluded all periproce-
ural MIs whereas Mayo only excluded Q-wave MIs).
Based on these important observational data from a center
idely acknowledged for excellence in PCI and which serves to
alidate the quality of PCI in COURAGE, there can no longer be
ny debate that optimal medical therapy is the cornerstone of
anagement for all patients with stable coronary artery disease and
hould be the initial management strategy as concluded by the
OURAGE study. We also enthusiastically concur with Hilliard
t al. (1) that contemporary PCI is even safer and more efficacious
han in the bare-metal stent era and is an important complement
o optimal medical therapy for symptom relief in patients with
ngina that cannot be controlled by medications. Despite these
dvances, it is also noteworthy to emphasize that there has been no
hange in the unadjusted rates of mortality or the combined end
oint of death or MI in the drug-eluting stent era (2003 to 2006)
s compared with the bare-metal stent era (1997 to 2003) in the
ayo observational experience. Lastly, the hypothesis that coro-
ary revascularization improves prognosis in patients with severe
schemia is intriguing, but remains unproven, and must be evalu-
ted in a rigorously designed and performed randomized clinical
rial.
Steven P. Sedlis, MD
illiam E. Boden, MD
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eply
e thank Drs. Sedlis and Boden for their interest in our article in
ACC: Cardiovascular Interventions (1). Although we agree that our
tudy suggests that “COURAGE-like” results are being achieved
n clinical practice, the analysis was not intended to investigate the
eneralizability of the trial (1,2). It is reasonable to propose that
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567utcomes would be even better if “optimal medical therapy,” as
dministered in the COURAGE (Clinical Outcomes Utilizing
evascularization and Aggressive Drug Evaluation) study, was
sed, though this requires additional resources to establish an
ntense case management approach.
We thank Drs. Sedlis and Boden for highlighting the fact that
here were additional differences between our cohort and that of
he trial; however, it is not possible to accurately compare the risk
rofiles of the 2 groups. That said, the (mean) age, one of the most
mportant determinants of procedural risk and long-term out-
omes, was 5 years greater in the Mayo Clinic cohort. Drs. Sedlis
nd Boden also state that a minority of our cohort had a positive
tress test. This is not accurate. Thirteen percent of patients had a
ositive stress as the predominant indication for percutaneous
oronary intervention (PCI), but other patients also had positive
tress tests but this was not the primary indication for referral and
herefore not included in the variable they quote. Fifty percent of
ur cohort had Canadian Cardiovascular Society class III/IV
ngina indicating that these patients had a significant ischemic
urden, and thus, we do not concur with the conclusion of Drs.
edlis and Boden that the Mayo Clinic registry and COURAGE
rial cohorts were comparable with respect to their risk profile.
Differences in procedural success may, in part, have been due to
he definitions used. Drs. Sedlis and Boden point out that in
OURAGE, “all periprocedural MIs” were excluded. However,
linical success (equating to our procedural success) was defined as
ngiographic success plus the absence of in-hospital myocardial
nfarction (some likely to be procedural myocardial infarction in an
lective PCI population), emergency coronary artery bypass graft,
r death in COURAGE.
Stable coronary artery disease represents a wide spectrum of
atients with heterogeneous severity of symptoms and risk. Thus,
e do not support the recommendation that all patients with stable
oronary artery disease should initially be managed with medical
herapy (3). This is important because patients in COURAGE
ere randomized after coronary angiography was performed.
igh-risk patients, such as those with class IV angina, markedlyositive stress test, refractory heart failure, cardiogenic shock, and
n ejection fraction of less than 30% were excluded. Therefore, we
ecommend that the decision regarding medical therapy versus
CI should be based on the severity of symptoms and risk
tratification. It is our belief that PCI is very effective in treating
ngina and improving functional status, and medical therapy is not
uperior to PCI in the management of stable coronary artery
isease (3).
We agree that the use of drug-eluting stents (DES) does not
educe the likelihood of death of myocardial infarction, but DES
educe the need for target lesion revascularization. As such, there
s a distinct possibility that symptom control would have been
uperior in the PCI arm of COURAGE had DES been used.
wenty-one percent of the PCI group required repeat revascular-
zation during follow-up, a rate that would have likely been
ignificantly lower had DES been used. Thus, the superiority of
CI with respect to improved relief in angina in the COURAGE
ay have been sustained for a longer period with DES use.
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nthony Hilliard, MD
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